Peer-reviewed veterinary case report
Vinorelbine treatment for skin mast cell tumors in dogs
By Grant, I A et al.·Published in Journal of veterinary internal medicine·2008·Department of Surgical and Radiological Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
- Species:
- dog
Plain-English summary
A group of 24 dogs with skin tumors called mast cell tumors were treated with a drug called vinorelbine to see if it could help shrink the tumors. Out of the dogs treated, 3 showed some improvement, with one dog having a complete response where the tumor disappeared, and another having a partial response. However, many dogs experienced side effects, including low white blood cell counts and gastrointestinal issues like vomiting and diarrhea. While vinorelbine showed some effectiveness, more research is needed to find out if using it in combination with other treatments could work better.
People also search for: dog mast cell tumor treatment · vinorelbine side effects in dogs · skin tumors in dogs treatment
Abstract
BACKGROUND: Few effective drugs are available to treat dogs with locally aggressive or metastatic mast cell disease. HYPOTHESIS: Vinorelbine, a semisynthetic derivative of vinblastine, is an effective drug for the treatment of canine mast cell tumors (MCT). ANIMALS: Twenty-four dogs with cutaneous MCT. METHODS: Dogs with at least 1 measurable, cytologically confirmed, and previously untreated cutaneous MCT received a single treatment with vinorelbine at the previously established dosage of 15 mg/m2 IV. Tumor measurements and CBC were evaluated before and 7 days after treatment. Adverse events were graded according to Veterinary Cooperative Oncology Group (VCOG) guidelines. STATISTICS: Data were accrued in accordance with a Simon's 2-stage design with a noninteresting response rate of .05, a target response of .25, and alpha and beta values of .10. RESULTS: Three of 24 dogs (13%) had a response to treatment, including 1 measurable complete response and 1 measurable partial response. The 3rd dog had microscopic complete response to treatment with stable measurable disease. Twenty other dogs (83%) had stable disease and 1 dog (4%) had progressive disease. Neutropenia occurred in 13 dogs (54%) (grade 1, n = 4; grade 3, n = 6; grade 4, n = 3). Gastrointestinal toxicity occurred in 11 dogs (46%) (anorexia: grade 1, n = 3; grade 2, n = 1; grade 3, n = 1; diarrhea: grade 1, n = 2; grade 3, n = 1; vomiting: grade 1, n = 5; grade 3, n = 1). CONCLUSIONS AND CLINICAL IMPORTANCE: Vinorelbine was associated with an overall response rate of 13% and a high prevalence of neutropenia. Additional studies are indicated to determine if repeated dosing of vinorelbine or combination of vinorelbine with other drugs increases the observed biologic activity against canine MCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18312556/